Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds Reuters
A Boston jury has delivered a major blow to Takeda Pharmaceutical, holding the company accountable for $885 million in damages for its role in delaying a generic version of the constipation drug Amiti